ACE-031 is a niche body-shaping peptide in the fitness community, but highly favored by savvy users. It's in the same category as Follistatin 344, focusing on advanced muscle optimization. It doesn't aim for exaggerated results or excessive enhancement; its core focus is on cleanly and effectively optimizing muscle ratios, reducing ineffective fat, and refining body lines. Having worked with raw materials for so long, I genuinely believe it's a treasure peptide for those wanting to achieve a lean, muscular physique, say goodbye to bulkiness, and break through body plateaus. It's suitable for those with a long-term training habit and who pursue a high-quality physique.
Core Advantages and Functions
Significant data has been obtained in humans: In healthy postmenopausal women, a single injection of 3 mg/kg subcutaneously resulted in an approximately 3.3% increase in overall lean body mass and a 5.1% increase in thigh muscle volume after 29 days (DXA + MRI measurements). Studies in DMD boys also showed an upward trend in lean body mass/bone mineral density-one of the few hard data points that have proven the myostatin pathway can effectively reduce its effects in humans.
More "systematic" than FS-344: FS-344 binds myostatin and activin, while ACE-031 also targets BMP9/10, resulting in a 16% increase in body weight and a 26–46% increase in single muscle mass in preclinical mice-far more potent than selective anti-myostatin antibodies.
With a half-life of 10–15 days, theoretically, one injection every two weeks is sufficient, eliminating the need for daily injections.
However-this is where it failed: the inadvertent inhibition of BMP9/10 disrupts vascular endothelium (ALK1 pathway). In the Phase 2 DMD trial, the high-dose group experienced nosebleeds, gum bleeding, telangiectasia, and erythema. The trial was halted in April 2011, and in 2013, Acceleron+Shire officially abandoned the entire project, never to be revived. Currently, none of the "ACE-031" research vials sold in the industry are the original Acceleron biologics from back then. Purity, glycosylation, and Fc folding are all unreliable.
Storage Conditions
As a recombinant fusion protein, it is much more delicate than small peptides:
Unreconstituted lyophilized powder: -20℃ freeze-dried powder can last 24–36 months (some manufacturers specify 48 months), 2–8℃ freeze-dried powder can last 12–24 months. Keep away from light, dry, and sealed in the original vial. Note-some protein manuals explicitly state not to freeze, but ACE-031 research grade is generally sold as -20℃ lyophilized powder; refer to the vial label. The key is to avoid repeated freeze-thaw cycles.
After reconstitution: Refrigerate at 2–8℃ away from light. Absolutely do not freeze. Use within 14–28 days (conservatively 14 days). Slowly push BAC water or sterile water/PBS along the bottle wall, gently roll to dissolve, do not vortex. The Fc segment and decoy structure are sensitive to shear force; freeze-thaw cycles will cause aggregation and permanent inactivation.
Do not reconstitute at too high a concentration (~0.5 mg/mL is common). For low concentrations, add 0.1% BSA to prevent adsorption to the bottle wall. The solution should be clear and colorless; discard immediately if cloudy/flocculated/discolored.
Precautions
This is clinically dead, not an "approved old drug": FDA/EMA has not approved any indications, WADA lists it as S4.3 (prohibited for gene/peptide drugs). Active athletes, military personnel, police officers, and those undergoing pilot recruitment physical examinations should avoid it. Research-grade vials are laboratory consumables, not human medication.
The vascular side effects are inherent to the mechanism, not due to impurities or toxins: nosebleeds, gum bleeding, small red blood vessels on the face and oral mucosa (telangiectasia), skin erythema-mild cases are reversible upon discontinuation, but no one knows how amplified the effects would be if a research-grade vial were injected into a human body. Those with bleeding tendencies, taking anticoagulants/antiplatelet therapy, uncontrolled hypertension, or vascular malformations (such as hereditary hemorrhagic telangiectasia) should avoid this product.
It can also impair the reproductive axis (activin binding → FSH/LH disturbance) and bone remodeling signals; there is absolutely no data on its long-term effects on individuals. Pregnant women, breastfeeding mothers, those with active tumors, and those with autoimmune diseases should avoid it altogether.
The widely circulated claim of "1–3 mg/kg subcutaneously every 10–14 days" is based on preclinical and discontinued Phase 1 doses and lacks safety window verification. Anyone attempting to use it in combination with IGF-1LR3 to "explode muscle" will likely experience nosebleeds and puncture wound swelling first, rather than the physique of a Belgian Blue bull.
The source is even more complex than FS-344: a 57 kDa fusion protein recombinant expression + correct folding + glycosylation. Small workshops simply cannot produce original-quality results. The "≥98% HPLC" on the COA is a joke for proteins-HPLC can only show purity, not folding and biological activity.
To put it bluntly, ACE-031 is a specimen in the history of myostatin inhibition that "proves humans can dismantle muscle brakes, but also proves that dismantling too much will cause nosebleeds." Its lean body mass data is truly impressive, but since 2011, the mainstream medical community has shelved it, and now it only circulates as a legend in the research chemistry market and fitness forums. The previous ones (PT-141, TB-500, Sermorelin, Ipamorelin) at least have FDA approval or long-term clinical experience, and FS-344 at least has animal and a small amount of human data from muscular dystrophy AAV. ACE-031 is a project that even the original researchers buried themselves. Taking research vials and injecting them into themselves is like stepping on brake wreckage that is already known to leak.
Hot Tags: chinese research-specific peptide ace-031 1mg/vial, China chinese research-specific peptide ace-031 1mg/vial manufacturers, suppliers, factory
